Uncategorized
VIDEO: CLS-TA, aflibercept combo reduced treatment burden compared with aflibercept alone
FORT LAUDERDALE, Fla. — At the Retina World Congress, Arshad M. Khanani, MD, MA, discusses results from the phase 2 prospective randomized TYBEE study, which showed that CLS-TA (Clearside Biomedical) in combination with aflibercept had similar visual acuity outcomes, lessened fluid as seen on OCT and reduced the number of injections needed compared with aflibercept alone.